Payment overview · 2025
General Payments
1 reported records · 1 companies
Healthcare provider profile · identity verified
Allopathic & Osteopathic Physicians|Family Medicine|Adult Medicine · ANACONDA, MT · NPI 1497802797
Verified facts
CMS Open Payments records show Roger Pafford, M.D. received $23.28 in general payments during 2025 across 1 reported records.
Inspire Medical Systems, Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
1 reported records · 1 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $23.28 | 100.0% | 1 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $23.28 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $23.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 258 | 49 |
| Atorvastatin Calcium | Atorvastatin Calcium | 230 | 44 |
| Lisinopril | Lisinopril | 221 | 60 |
| Omeprazole | Omeprazole | 174 | 44 |
| Metformin Hcl | Metformin Hcl | 167 | 41 |
| Amlodipine Besylate | Amlodipine Besylate | 157 | 40 |
| Simvastatin | Simvastatin | 151 | 44 |
| Losartan Potassium | Losartan Potassium | 105 | 29 |
| Gabapentin | Gabapentin | 95 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 86 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 86 | 24 |
| Donepezil Hcl | Donepezil Hcl | 81 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 77 | 19 |
| Potassium Chloride | Potassium Chloride | 73 | 13 |
| Metformin Hcl Er | Metformin Hcl | 72 | 14 |
| Trazodone Hcl | Trazodone Hcl | 68 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 65 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 64 | 19 |
| Myrbetriq | Mirabegron | 58 | suppressed |
| Allopurinol | Allopurinol | 56 | suppressed |
| Eliquis | Apixaban | 56 | suppressed |
| Tradjenta | Linagliptin | 55 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 54 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | suppressed |
| Glipizide | Glipizide | 47 | 13 |
| Meloxicam | Meloxicam | 45 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Xarelto | Rivaroxaban | 44 | suppressed |
| Furosemide | Furosemide | 39 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 39 | suppressed |
| Spironolactone | Spironolactone | 39 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Prednisone | Prednisone | 25 | 18 |
| Carvedilol | Carvedilol | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Azithromycin | Azithromycin | 23 | 11 |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $23.28 · 1 records | Inspire Medical Systems, Inc. | INSPIRE | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error